Check out the Detailed Program! Learn More

Screening for esophageal cancer in high-risk populations

Most oesophageal cancers are diagnosed after symptoms appear, when treatment is often more complex. High-risk screening aims to identify precancerous change, especially Barrett’s oesophagus, before invasive cancer develops. Its value depends on effective follow-up.

Australia has a national bowel cancer screening programme but no equivalent for oesophageal cancer. Upper gastrointestinal endoscopy is invasive, requires sedation and specialist capacity, and has not shown the same population-level benefit for average-risk adults. Defined risk factors need a different pathway.

ISDE 2021 highlighted how genetics, inherited susceptibility and environmental exposures interact across the disease pathway. Its sessions underlined why surveillance policy must follow evidence and local capacity rather than offer an untargeted test to everyone.

Who is at higher risk?

Risk factors include Barrett’s oesophagus, long-standing reflux with warning features, heavy alcohol use, tobacco exposure, obesity, achalasia, caustic injury and previous head-and-neck cancer. Age and male sex increase risk but do not justify screening alone. Reflux alone commonly leads to unnecessary anxiety and private endoscopy.

Access also shapes risk. Higher incidence and poorer survival are well documented in Aboriginal and Torres Strait Islander communities, while remote residents may live far from endoscopy services. Smoking and harmful alcohol use are common in some communities, so screening must accompany prevention, culturally safe care and practical access.

What screening can find

Endoscopic screening can visualise the oesophagus, obtain biopsies and detect Barrett’s oesophagus or dysplasia before cancer appears. Blood tests, symptom questionnaires and genetic markers may help assess selected patients, but none replaces endoscopy. A biopsy showing no dysplasia does not remove the need for risk-factor management.

The boundary between screening and diagnosis is crucial. Difficulty swallowing, persistent reflux, vomiting blood, unexplained weight loss or anaemia may indicate disease and require prompt endoscopic assessment. Symptoms are unreliable screening tools because early cancer may cause none, while common symptoms usually arise from benign conditions.

When family history changes risk

Family history deserves careful review, particularly when oesophageal cancer occurred young or in several close relatives. Genetic conditions such as hereditary diffuse oesophageal cancer can confer substantial risk, while variants affecting cell repair may increase susceptibility through Barrett’s oesophagus. These patterns can justify specialist assessment without creating a generic rule for every relative.

Congress coverage of genetic predisposition and cancer explains how inherited susceptibility may shape both risk and surveillance. Shared smoking, alcohol use and diet can also cluster within families. Genetic counselling can distinguish inherited disease from environmental exposure, while relatives of someone with a pathogenic variant may need testing after specialist review.

Starting with an Australian GP

In Australia, risk assessment commonly begins with a GP, who can review reflux, medicines, smoking, alcohol, weight and family history. A Medicare-covered or bulk-billed consultation can lead to a gastroenterology referral, although public waiting lists, private costs and limited fly-in fly-out endoscopy affect access. Telehealth assists initial assessment but cannot replace endoscopy when indicated.

For people in Darwin, Alice Springs, regional New South Wales and other remote locations, coordinated specialist outreach and travel support determine whether surveillance is feasible. Aboriginal health services should lead culturally safe discussions about symptoms and family history. Consent, privacy and clear explanations are especially important where distrust of health services reflects past discrimination.

How surveillance is organised

After referral, a gastroenterologist usually performs high-definition endoscopy, documents the extent of Barrett’s oesophagus and obtains targeted biopsies. Dysplasia is graded and may prompt endoscopic treatment, ablation or closer review. Pathology follow-up and accurate record-sharing are essential so that no patient is lost between testing and surveillance.

Intervals are not uniform. Long-segment Barrett’s oesophagus, confirmed dysplasia, inherited susceptibility and previous treatment can require more frequent endoscopy, while limited nondysplastic disease may be reviewed less often. Australian guidance and specialist judgement determine the schedule; a rigid interval should not replace the pathology and clinical context.

Comparing the main pathways

The appropriate pathway depends on why someone is at risk. Established disease, inherited susceptibility and symptom-driven assessment have different evidence bases, goals and follow-up requirements. Screening is useful only when a positive result leads to diagnosis, treatment and reliable recall.

Group Initial approach Typical follow-up
Established Barrett’s oesophagus High-definition endoscopy with biopsies Specialist surveillance based on length and dysplasia
Hereditary or strong family risk Specialist assessment, possible genetic testing and endoscopy Individualised surveillance; family testing when indicated
High-risk symptoms Prompt diagnostic endoscopy rather than screening Depends on findings; treatment and close review if cancer or dysplasia is found
Achalasia, caustic injury or prior head-and-neck cancer Specialist assessment and targeted upper-GI evaluation Condition-specific surveillance where evidence supports it
Average risk without warning features No routine oesophageal screening Address reflux, smoking and alcohol; investigate symptoms promptly

These pathways should not be confused. Surveillance may be repeated in an asymptomatic person with proven risk, whereas diagnosis investigates a symptom. Where evidence is uncertain, specialists should explain the expected benefit, uncertainty and alternatives.

What to remember

High-risk screening is strongest when targeted at a defined group and linked to specialist care. Barrett’s oesophagus is the clearest example, while hereditary syndromes and previous upper-GI conditions require individual decisions. For average-risk Australians, routine endoscopy cannot replace stopping smoking, reducing harmful alcohol use and managing reflux.

The central lesson from ISDE 2021 is that risk assessment, careful endoscopic surveillance and prevention belong in one connected pathway. The key distinction for Australia is between surveillance of proven high-risk disease, prompt investigation of symptoms and no blanket screening for everyone else.

About ISDE

The ISDE is an international, multispecialty society devoted to the study of the esophagus in disease and in health that was founded in 1979. The aims of the ISDE are to promote the exchange of scientific and medical knowledge among specialists in the field, to maintain interchange with organizations and industries, and to encourage basic and clinical research in fields related to the esophagus. In order to promote the professional and educational development of individuals interested in the esophagus, the ISDE sponsors its own journal, international congresses, and other educational programs. The ISDE Secretariat was in Tokyo, Japan, from 1979 to 2004, and then resided in Los Angeles, California, from 2004 through 2010. Since 2010 the Secretariat has been in Vancouver, British Columbia, under the auspices of International Conferences Service, Ltd. The ISDE welcomes participation by existing members and encourages individuals who are professionally interested in the esophagus to become members. Benefits include reduced registration fees at our congresses and other educational offerings, restricted access to website content and member search capability, access to webcasts, reduced subscription rates for our journal, and the opportunity to help lead this organization into a position of leadership in the worldwide medical community.